Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGHT-COPD: Aclidinium/Formoterol FDC in COPD
NCT01078623Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of aclidinium and formoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Day 14. Started Feb 2010; status: completed.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01078623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01078623.